Table 2.
Inpatient outcomes and antithrombotic medication use stratified by race/ethnicity
| Characteristics | Race/ethnicity |
P value | ||||
|---|---|---|---|---|---|---|
| Asian | Black, non-Hispanic | Hispanic | Other | White, non-Hispanic | ||
| No. of patients (% of total cohort) | 236 (1.2) | 915 (4.6) | 639 (3.2) | 711 (3.5) | 17,564 (87.5) | |
| Ischemic stroke, systemic embolism, and intracranial hemorrhage | <5∗ | 6 (0.7) | 7 (1.1) | 8 (1.1) | 130 (0.7) | .43 |
| Bleeding requiring transfusion | 12 (5.1) | 92 (10.1) | 55 (8.6) | 43 (6.0) | 1,349 (6.7) | .0002 |
| Pericardial effusion | ||||||
| Any | 13 (5.5) | 43 (4.7) | 23 (3.6) | 24 (3.4) | 598 (3.4) | .23 |
| Requiring drainage | 5∗ | 16 (1.7) | 3 (0.5) | 5 (0.7) | 187 (1.1) | .12 |
| Cardiac arrest and death | <5∗ | 6 (0.7) | 6 (0.9) | 0 | 44 (0.3) | <.0001 |
| Length of stay (d) | 1.3 ± 1.5 | 1.5 ± 1.5 | 1.4 ± 2.1 | 1.3 ± 1.0 | 1.3 ± 1.4 | <.0001 |
| Antithrombotic medications | ||||||
| Warfarin plus antiplatelet | 49 (20.8) | 259 (28.3) | 138 (21.6) | 187 (26.3) | 4,492 (25.6) | <.0001 |
| DOAC plus antiplatelet | 66 (28.0) | 247 (27.0) | 202 (31.6) | 193 (27.1) | 4,817 (27.4) | |
| Warfarin only | 16 (6.8) | 107 (11.7) | 43 (6.7) | 90 (12.7) | 1,887 (10.7) | |
| DOAC only | 47 (19.9) | 118 (12.9) | 85 (13.3) | 82 (11.5) | 2,414 (13.7) | |
| Dual antiplatelet therapy | 14 (5.9) | 65 (7.1) | 73 (11.4) | 50 (7.0) | 1,038 (5.9) | |
| Other | 44 (18.7) | 119 (13.0) | 98 (15.3) | 109 (15.3) | 2,916 (16.6) | |
Values are given as n (%) or mean ± SD unless otherwise indicated.
DOAC = direct oral anticoagulant.
∗
Per the cell suppression policy of the Premier Healthcare Database (PHD), counts <5 are not reported.